February 12, 2024 11:16 AM EST

Immunovant's plans for autoimmune asset; Wall Street worries about Moderna’s RSV candidate

Plus, news about Novo Holdings, Gritstone Bio, Invivyd and Science 37:

Immunovant outlines big plans for its autoimmune program: The biotech

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Im­muno­van­t's plans for au­toim­mune as­set; Wall Street wor­ries about Mod­er­na’s RSV can­di­date